Koss Olinger Consulting LLC Has $415,000 Stake in MiMedx Group, Inc $MDXG

Koss Olinger Consulting LLC decreased its position in MiMedx Group, Inc (NASDAQ:MDXG) by 7.1% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 67,938 shares of the company’s stock after selling 5,154 shares during the period. Koss Olinger Consulting LLC’s holdings in MiMedx Group were worth $415,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Strs Ohio acquired a new position in MiMedx Group in the 1st quarter worth approximately $595,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in MiMedx Group by 18.1% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,713 shares of the company’s stock worth $302,000 after purchasing an additional 6,090 shares during the period. Harbor Capital Advisors Inc. boosted its stake in MiMedx Group by 12.0% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 1,169,195 shares of the company’s stock worth $7,144,000 after purchasing an additional 125,519 shares during the period. New York State Common Retirement Fund boosted its stake in MiMedx Group by 51.8% in the 1st quarter. New York State Common Retirement Fund now owns 87,781 shares of the company’s stock worth $667,000 after purchasing an additional 29,941 shares during the period. Finally, HB Wealth Management LLC acquired a new position in MiMedx Group in the 2nd quarter worth approximately $156,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on MDXG shares. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Cantor Fitzgerald increased their target price on shares of MiMedx Group from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

MiMedx Group Stock Down 0.4%

MiMedx Group stock opened at $6.73 on Tuesday. The company has a market capitalization of $995.77 million, a P/E ratio of 32.05 and a beta of 1.73. The firm’s fifty day simple moving average is $6.98 and its 200-day simple moving average is $6.77. The company has a current ratio of 4.39, a quick ratio of 3.90 and a debt-to-equity ratio of 0.08. MiMedx Group, Inc has a 1-year low of $5.69 and a 1-year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.03) earnings per share for the quarter. The business had revenue of $67.69 million for the quarter. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. Sell-side analysts forecast that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.